Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995784 | 0.82 | CA2 (0.32) | — | |
| SCHEMBL16797539 | 0.81 | — | — | |
| SCHEMBL16797618 | 0.81 | — | — | |
| SCHEMBL16797528 | 0.81 | — | — | |
| SCHEMBL15610455 | 0.79 | — | — | |
| SCHEMBL7598022 | 0.77 | THRB (0.33) | — | |
| SCHEMBL4179634 | 0.77 | — | — | |
| SCHEMBL13573090 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL31480605 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL9117823 | 0.76 | GPR84 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| CN-114867726-B | Small molecule inhibitors of KRAS G12C mutants | 默沙东有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-20040116685-A1 | Method for solution phase synthesis of oligonucleotides | PROLIGO LLC | 2004-06-17 | — | — | US | disclosed |
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0996627-A4 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES | PROLIGO L L C (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6262251-B1 | PRODUCT ANCHORED SEQUENCIAL SYNTHESIS (PASS); AN ANCHOR GROUP ATTACHED TO THE 5' END OF THE GROWING OLIGONUCLEOTIDE PRODUCT ALLOWS THE COUPLED PRODUCT TO BE SEPARATED FROM UNREACTED STARTING MATERIALS | PROLIGO LLC | 2001-07-17 | — | — | US | disclosed |
| EP-0979233-A4 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO L L C (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0996627-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES | Proligo L.L.C. (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0979233-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NeXstar Pharmaceuticals, Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| US-6001966-A | REACTING N-TERMINAL PROTECTED AMINO ACID WITH PEPTIDE STARTING MATERIAL FORMING A PEPTIDE PRODUCT, PARTITIONING FROM UNREACTED MATERIAL AND REAGENTS BASED ON PRESENCE OF N-TERMINAL BLOCKING/ANCHORING GROUP | PROLIGO LLC (US) | 1999-12-14 | — | — | US | disclosed |
| US-5874532-A | USING A N-TERMINAL PROTECTED AMINO ACID MONOMER | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998047910-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0863910-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NeXstar Pharmaceuticals, Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998030578-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1997014706-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-5332807-A | Process of producing 8A- and 9A-azalide antibiotics | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| WO-1993020094-A1 | HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR QUINOLINE | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | TSHR 1840/4885 |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | STING1, PDCD1LG2, CD274 | TSHR 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.